Share this video  

ESMO 2022 | Updated analysis of DESTINY-Gastric02: T-DXd in HER2+ GEJ cancer who progressed with trastuzumab

Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shared the overall-survival and updated efficacy and safety results of the Phase II DESTINY-Gastric02 (NCT04014075) trial exploring trastuzumab deruxtecan (T-DXd) in western patients with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. The primary endpoint was confirmed objective response rate (cORR). Secondary endpoints included progression-free survival (PFS), duration of response (DOR), OS, and patient-reported outcomes. Primary results demonstrated a cORR of 38.0%. Median duration of follow-up was 10.2 months at data cut-off. Median OS was 12.1 months and 12-month OS rate was 50.6%. cORR was 41.8%. Median DOR was 8.1 months. Median PFS was 5.6 months. Overall, T-DXd continued to show significant clinical benefit and a tolerable safety profile in the treatment of patients with HER2+ unresectable/metastatic gastric/GEJ cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.